The efficacy and safety of ustekinumab in special cases with Crohn′s disease
10.3760/cma.j.cn101480-20210309-00019
- VernacularTitle:乌司奴单克隆抗体在合并特殊情况克罗恩病患者中治疗有效性和安全性的病例分析
- Author:
Yubei GU
1
;
Lei TU
;
Tianyu ZHANG
;
Jie ZHONG
;
Huan WANG
;
Liangru ZHU
Author Information
1. 上海交通大学医学院附属瑞金医院消化内科，上海 200025
- Publication Type:Journal Article
- Keywords:
Crohn′s disease;
Biologics;
Ustekinumab;
Tuberculosis;
Malignancy
- From:
Chinese Journal of Inflammatory Bowel Diseases
2021;05(3):262-266
- CountryChina
- Language:Chinese
-
Abstract:
Anti-tumor necrosis factor-α biologics have been widely used in the treatment of Crohn′s disease. A variety of new biological agents have been approved this year and entered clinical use.Clinical benefits and risks should be fully balanced according to the disease conditions for special population, and shared decision making should be conducted to select appropriate biological agents and develop individualized treatment regimen which will help to improve efficacy and safety of biologics.
